2024-12-16 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison & Overview:**

Johnson & Johnson is a multinational pharmaceutical, medical devices, and consumer goods company.  The cumulative return of JNJ (25.34%) significantly underperformed the S&P 500 (VOO) cumulative return (120.91%) over the analyzed period. The difference is -95.6%, placing it at the 1st percentile of its historical range relative to the S&P 500.  The provided alpha consistently shows negative values suggesting underperformance against the market benchmark across the analyzed years. The beta values are not provided. The market capitalization has generally increased over the years.


**2. Recent Price Movement:**

* **Closing Price:** $146.62
* **5-day Moving Average:** $147.67
* **20-day Moving Average:** $151.62
* **60-day Moving Average:** $156.68

The stock price is currently below all three moving averages, indicating a bearish short-term trend.

**3. Technical Indicators & Expected Return:**

* **RSI:** 18.54 (Suggests the stock is oversold)
* **PPO:** -0.32 (Suggests bearish momentum)
* **20-Day Relative Divergence:** +1.0 (Short-term upward trend)

The low RSI and negative PPO suggest bearish sentiment. However, the positive relative divergence suggests a potential short-term upward correction.  The expected return is 0.0%, implying no significant outperformance relative to the S&P 500 is expected over the long term (2+ years) based on the given data.  The price of $146.62 does not suggest any dramatic recent price movement (no rapid increase or decrease indicated).


**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility in EPS, with a significant drop in the most recent quarter (2024-10-23).

* **EPS Trends:**  EPS fluctuated between $1.12 and $1.95 in the last four quarters, showing no clear trend.  There is a significant drop from $1.95 to $1.12 between July and October 2024.
* **Revenue Growth Trends:** Revenue remains relatively stable around $21-22.5 billion. There is no significant growth trend observed in the recent quarters.
* **Quarterly Comparison:**  There's no consistent pattern in the comparison of quarterly results. The October 2024 earnings reveal a dramatic decrease in EPS while revenue remained roughly stable.  A detailed analysis requires more context such as expected values for comparison.

**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue is relatively consistent, hovering around $21-22.5B.  Profit margins are high and generally stable, ranging from 68.23% to 69.55%.  There's a slight downward trend in recent quarters.
* **Capital and Profitability:** Equity shows some fluctuation. ROE is highly variable, most notably, a spike to 36.54% in Q3 2023, followed by considerably lower values in subsequent quarters.  This warrants further investigation into the underlying reasons for this significant variation.


**6. News and Recent Issues:**

No specific news or recent market outlook data, analyst opinions, or performance highlights were provided. To complete this section,  current news sources and financial analysis sites should be consulted.


**7. Overall Analysis:**

JNJ's performance has significantly lagged the S&P 500 recently. Technical indicators suggest an oversold condition and bearish momentum, though a short-term upward trend is possible.  Earnings show some recent volatility, particularly a significant drop in EPS in the latest quarter which requires further investigation for context. Financial data reveal generally healthy profitability and consistent revenue, although the significant swings in ROE need further analysis.  More context (e.g., industry comparisons, analyst expectations) is needed for a comprehensive assessment.  The lack of current news and market outlook prevents a complete picture.  Without additional information, it's difficult to offer a definitive investment recommendation.

**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investing involves risk, including the potential loss of principal.  Always conduct thorough due diligence and consider consulting a financial advisor before making any investment decisions.
